Compare UiPath Inc (PATH) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Regeneron Pharmaceuticals Inc — how do they compare? UiPath Inc trades at $13.58 (market cap $7.26B), while Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 11.5× UiPath Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| PATH | REGN | |
|---|---|---|
Market Cap | $7.26B | $83.43B |
Sector | Technology | Health |
52-Week High | $19.29 | $852.03 |
52-Week Low | $9.38 | $555.51 |
Enterprise Value | $6.05B | $78.14B |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) is trading at $14.01, down 7.77% in the last 24 hours amid mixed technical signals and earnings volatility. The stock shows improving fundamentals with revenue growing from $892M in 2022 to $1.43B in 2025, though profitability remains negative with a -$73.69M net income. Recent Q2 2026 earnings beat expectations but guidance concerns triggered a selloff, with technical indicators showing bearish momentum despite oversold RSI conditions.
PATH presents a turnaround opportunity with strong revenue growth and improving margins, but faces execution risks in competitive AI automation. Analyst consensus targets $17.38 (24% upside) despite cautious ratings, with institutional interest growing. Key risks include sustained profitability challenges and AI competition, while positive cash flow trends and strategic positioning in enterprise automation offer long-term potential.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
